C-F. Chung

Statistics

Publications

Citations

163

H-Index

Active since

2021

Affiliations

National Cheng Kung University Hospital(Current)

University of Milan

AstraZeneca (United States)

Sarah Cannon

Samsung Medical Center

C-F. Chung is an author at National Cheng Kung University Hospital specializing in metastasis, her2-positive metastatic disease, and her2-positive breast cancer therapy.

Publications per year

2021–2024

Publications

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

Javier Cortés, S-B. Kim, W-P. Chung et al. · Annals of Oncology · 2021 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

Sara A. Hurvitz, S.-B. Kim, Wei‐Pang Chung et al. · ESMO Open · 2024 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17

1–2 of 2